Cullinan Oncology to Participate in Upcoming Investor Conferences
27 févr. 2024 08h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies,...
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
18 déc. 2023 16h53 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology...
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
14 déc. 2023 16h30 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology therapies, today announced...
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
08 nov. 2023 07h00 HE
|
Cullinan Oncology, Inc.
Cullinan to provide clinical data updates on three novel targeted oncology programs and complete enrollment in the pivotal Phase 2b portion of the zipalertinib REZILIENT1 study in 2024 Initial...
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
03 nov. 2023 12h01 HE
|
Cullinan Oncology, Inc.
Five abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer 2023 Annual Meeting Preliminary clinical biomarker data for anti-MICA/B antibody, CLN-619, supports proposed...
Cullinan Oncology to Participate in Upcoming Investor Conferences
30 oct. 2023 08h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies,...
Cullinan Oncology to Participate in Upcoming Investor Conferences
06 sept. 2023 08h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology...
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
10 août 2023 07h00 HE
|
Cullinan Oncology, Inc.
Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer (NSCLC) patients (REZILIENT-3) open to enrollment Initial monotherapy clinical data for...
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
09 août 2023 07h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that...
Cullinan Oncology to Participate in Upcoming Investor Conferences
31 juil. 2023 08h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies,...